Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
10 evidence topics · 15 sources
RINGSIDE Part B progression-free survival across subgroups
“Age ≤30 / >30 years” (opens the source at this quote in a new tab)
“Tumor location intra-/extra-abdominal” (opens the source at this quote in a new tab)
“CTNNB1 mutation (S45F+S45P T41A)” (opens the source at this quote in a new tab)
“Baseline tumor size >10 / ≤10 cm” (opens the source at this quote in a new tab)
“Prior systemic DT therapy (yes/no)” (opens the source at this quote in a new tab)
RINGSIDE Part A objective response by subgroup
DeFi progression-free survival across prespecified subgroups
CTNNB1 S45F mutation and recurrence after surgery
“The estimated 5-year recurrence-free survival rate was 23% (95% CI, 10 to 40%) for patients with 45F mutation compared to 57% (95% CI, 43 to 69%), and 65% (95% CI, 38 to 83%) for 41A mutation and nonmutated CTNNB1, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated 3-year and 5-year RFS rates were 0.49 and 0.45, respectively, for patients who had tumors with the S45F mutation; 0.91 and 0.91, respectively, for patients who had wild-type tumors; and 0.70 and 0.66, respectively, for all others” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This series confirmed that primary, completely resected, sporadic DTs with the S45F mutation have a greater tendency for local recurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 mutation, tumor size, and location during active surveillance
“In multivariable analysis, larger tumor size, mutation type, and tumor locations were associated with lower TFS. The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Initial tumor size, CTNNB1 mutation, and location should be factored into the initial decision-making process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor location and outcome of surgery compared with a wait-and-see approach
“The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age, tumor site, and tumor size and recurrence after resection
“In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin. Abdominal wall tumors had the best outcome (5-year LRFS 91%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Systemic therapies may be appropriate for young patients with large, extremity desmoids, but surgery alone is curative for most abdominal wall lesions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote